FIGURE 6.

CXC chemokine ligand 14 (CXCL14) siRNA nanoparticle provides therapeutic benefits for glioblastoma. (A) Fluorescence images of brain cortex from nude mice at 1 h after intravenous injection with a 5 nmol/kg dose of Dy677‐labeled siRNA‐loaded nanoparticles. Bars, 100 μm. (B,C) CXCL14 protein levels in the homogenized GBM8901 or GBM09T xenografts with or without scramble (Scr.) siRNA nanoparticles (NP), 2’OMe‐Scr. siRNA NP, CXCL14 siRNA NP, or 2’OMe‐CXCL14 siRNA NP treatment for three consecutive days on day 12 for GBM8901 xenografts or on day 21 for GBM09T xenografts after tumor implantation. Mice received tail vein injection with Scr. siRNA NP, 2’OMe‐Scr. siRNA NP, CXCL14 siRNA NP, or 2’OMe‐CXCL14 siRNA NP at a dose of 75 nmol/kg per day. Error bars, SD within triplicate experiments. **p < 0.01, ***p < 0.001, compared with untreated group. (D) Bioluminescent images (BLI) of GBM8901‐lucGFP or GBM09T‐lucGFP xenograft‐bearing mice received 2’OMe ‐Scr. siRNA NP or 2’OMe‐CXCL14 siRNA NP treatment on day 21 for GBM8901‐lucGFP xenografts or on day 27 for GBM09T‐lucGFP xenografts after tumor implantation. Mice were injected at a dose of 75 nmol/kg per day for five consecutive days on day 12 for GBM8901‐lucGFP xenografts or on day 21 for GBM09T‐lucGFP xenografts after tumor implantation into the tail vein. (E) Mean BLI values associated with longitudinal monitoring of tumor growth for each treatment group. Data are presented as means ± SD (n = 6–8). ****p < 0.001, compared to untreated mice. (F) Corresponding survival curves of GBM8901‐lucGFP or GBM09T‐lucGFP xenograft‐bearing mice for each treatment group